Regulatory delays for biosimilars in U.S.
Denosumab received CRL from FDA due to partner Alvotech's facility issues; Rituximab requires re-inspection. Both face delays of at least 6-12 months.
DRREDDY / Q3-FY26 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Lenalidomide revenue cliff from Q4
CEO advised to assume zero lenalidomide revenue from Q4 FY26, which will impact overall revenue and margins.
Semaglutide pricing pressure and competition
Management expects eventual competition in Canada and other markets, with pricing likely settling at lower end of $20-$70 range.
SG&A cost growth moderation uncertain
SG&A as % of revenue remains elevated at 30% (ex-one-off); management expects growth to moderate but absolute level may not decline.